Modality
Bispecific Ab
MOA
BCMA ADC
Target
IL-23
Pathway
Fibrosis
Parkinson'sT2D
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
~Apr 2018
→ ~Jul 2019
Phase 2
Oct 2019
→ Feb 2029
Phase 2Current
NCT08145273
1,477 pts·T2D
2025-06→2029-02·Active
NCT08923706
961 pts·Parkinson's
2019-10→2026-08·Active
2,438 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-09-206mo agoFast Track· T2D
2026-08-205mo awayPh3 Readout· Parkinson's
2029-02-142.9y awayPh3 Readout· T2D
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2/3
Active
P2/3
Active
Catalysts
Fast Track
2025-09-20 · 6mo ago
T2D
Ph3 Readout
2026-08-20 · 5mo away
Parkinson's
Ph3 Readout
2029-02-14 · 2.9y away
T2D
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08145273 | Phase 2/3 | T2D | Active | 1477 | EDSS |
| NCT08923706 | Phase 2/3 | Parkinson's | Active | 961 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Fixalucimab | Innovent Bio | Phase 1/2 | IL-23 | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Gelisertib | Samsung Biologics | Approved | IL-23 |